Endocrine Pathology

SJR Rank #492H-index: 65SJR: 3.715Best quartile: Q1APC: US$3,190
Journal website: aims, scope and author guidelines
Publisher

Springer

Country

United States

Type

journal

SJR by Edition

2022202500.951.92.853.8

Subject Categories

  • EndocrinologyQ1
  • Endocrinology, Diabetes and MetabolismQ1
  • Medicine (miscellaneous)Q1
  • Pathology and Forensic MedicineQ1

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Thyroid Cancer Diagnosis and TreatmentNeuroendocrine Tumor Research AdvancesPituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic TumorsNeuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismLung Cancer Research StudiesGrowth Hormone and Insulin-like Growth FactorsHead and Neck AnomaliesGlioma Diagnosis and Treatment

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs03570105140

Documents per Year

20222025015304560

Detailed Information

ISSN

1559-0097, 1046-3976

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

3.60

References per Document

39.59

Coverage

1990-2026

Scope

Endocrine Pathology publishes original articles on clinical and basic aspects of endocrine disorders. Work with animals or in vitro techniques is acceptable if it is relevant to human normal or abnormal endocrinology. Manuscripts will be considered for publication in the form of original articles, case reports, clinical case presentations, reviews, and descriptions of techniques. Submission of a paper implies that it reports unpublished work, except in abstract form, and is not being submitted simultaneously to another publication. Accepted manuscripts become the sole property of Endocrine Pathology and may not be published elsewhere without written consent from the publisher. All articles are subject to review by experienced referees. The Editors and Editorial Board judge manuscripts suitable for publication, and decisions by the Editors are final.

Metrics from SCImago Journal Rank 2025. View on SCImago